Mexico /
As time goes on, the clinical trials of covid-19 vaccines are gradually being updated and one of them is that of Moderna, which indicated that it is 90 percent effective against the disease and 95 percent against severe forms of the disease, the U.S. biotechnology company announced in new published results, slightly less than in a previous clinical trial.
the data come from a Phase 3 clinical trial in which more than 30,000 people participated in the United States. Efficacy is slightly lower than the 94.1 percent recorded in a large clinical trial published in the New England Journal of Medicine in December.
Moderna did not say in its statement whether the decrease in efficiency was due to the emergence of new variants, p.bre the biotechnology company is working on two modified versions of his vaccine, Specific for variants, with encouraging results in mice, but not yet peer-reviewed.
“New preclinical data on our candidates for variant-specific vaccines give us confidence in our ability to anticipate the emergence of new variants,” applauded the head of Moderna, Stephane Bancel.
As of April 12, Moderna said it had shipped 132 million doses of its covid vaccine worldwide, including 117 million to the United States.
It is still on track to supply an additional 100 million doses to Americans by the end of May, and another 100 million by the end of June.
The company’s clinical trial for teens ages 12 to 17 has about 3,000 participants in the United States, and its trial for children six months to 11 years old continues to recruit 6,750 participants in the United States. and China.
Bgpa